In the Pipeline

At Anziva Pharmaceuticals, our team is dedicated to developing several New Therapeutic Entities (NTEs) in our pipeline, with a focus on enhancing existing market products through:

• Performance enhancement
• Stability improvement
• Simplified manufacturing processes

Our efforts will lead to superior, cost-effective pharmaceutical products for our patients. By pursuing the FDA's 505(b)(2) pathway, we gain a strategic advantage, significantly reducing the time and financial investment compared to the traditional full New Drug Application (NDA) process. Stay tuned for exciting developments ahead!